Generations of commitment fuel engine of J Edgar and Son
In November 1919, Corporal Joseph Edgar returned to his West Cumbria home of Rowrah, demobbed from the army and ready for civilian life.
Stay updated with breaking news from Colitis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In November 1919, Corporal Joseph Edgar returned to his West Cumbria home of Rowrah, demobbed from the army and ready for civilian life.
Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.
Mirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis.
Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.